Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response

Conditions:   NSCLC;   Melanoma;   Kidney Cancer;   Urothelial Carcinoma;   Head and Neck Cancer Intervention:   Other: Breathprint analysis and patient-reported outcomes Sponsors:   University Health Network, Toronto;   University of Amsterdam Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials